<unk>  adverse events are considered somewhat manageable and the incidence of serious adverse events low. The most common adverse events associated with<unk>  therapy are fatigue, diarrhea, nausea, anorexia, hypertension, a yellow skin discoloration, hand-foot skin reaction, and stomatitis. In the placebo-controlled Phase III GIST study, adverse events which occurred more often with<unk>  than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation. Dose reductions were required in 50% of the patients studied in RCC in order to manage the significant toxicities of this agent. Serious (grade 3 or 4) adverse events occur in ≤10% of patients and include hypertension, fatigue, asthenia, diarrhea, and chemotherapy-induced acral erythema. Lab abnormalities associated with<unk>  therapy include lipase, amylase, neutrophils, lymphocytes, and platelets. Hypothyroidism and reversible erythrocytosis have also been associated with<unk> . Most adverse events can be managed through<unk> pportive care, dose interruption, or dose reduction. A recent study done at MD Anderson Cancer Center compared the outcomes of metastatic renal cell cancer patients who received<unk>  on the standard schedule (50 mg/4 weeks on 2 weeks off) with those who received<unk>  with more frequent and short drug holidays (alternative schedule). It was seen that the overall<unk> rvival, progression free<unk> rvival and drug adherence were significantly higher in the patients who received<unk>  on the alternative schedule. Patients also had a better tolerance and lower severity of adverse events which frequently lead to discontinuation of treatment of metastatic renal cell cancer patients.
Sunitinib
Ceritinib
Axitinib
Gilteritinib
Abrocitinib
Erdafitinib
Oclacitinib
Upadacitinib